OmniAb (NASDAQ:OABI) Releases Quarterly Earnings Results, Beats Expectations By $0.07 EPS

OmniAb (NASDAQ:OABI) issued its quarterly earnings data on Thursday. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.07, FiscalAI reports. OmniAb had a negative return on equity of 16.45% and a negative net margin of 115.12%.The firm had revenue of $13.41 million during the quarter, compared to the consensus estimate of $4.69 million.

Here are the key takeaways from OmniAb’s conference call:

• Q2 revenue rose to $13.4 million from $3.9 million year over year, driven primarily by partner milestone revenue; net loss narrowed to $5.9 million from $15.9 million.
• OmniAb raised and narrowed its 2026 guidance, now forecasting revenue of $32 million–$36 million, GAAP operating expenses of $84 million–$88 million, and year-end cash of $37 million–$41 million.
• The partnered pipeline continued to advance, with 425 active programs, 34 active clinical programs or approved products, four new clinical entrants in 2026, and approximately $340 million in remaining potential milestones tied to clinical-stage programs.
• The company sold two xPloration instruments during Q2, bringing the field total to four, and said the platform could generate recurring revenue from consumables, software, maintenance, and services.
• Revenue remains heavily dependent on milestone timing and was front-loaded in the first half of 2026; despite improved cash use, OmniAb expects to end the year with less cash than the $52 million held at the end of Q2.

OmniAb Trading Up 37.5%

Shares of OABI traded up $0.84 during trading hours on Friday, reaching $3.08. 2,672,840 shares of the stock traded hands, compared to its average volume of 402,782. The stock has a fifty day simple moving average of $2.26 and a 200 day simple moving average of $1.96. OmniAb has a 52 week low of $1.30 and a 52 week high of $3.12. The company has a market cap of $445.92 million, a price-to-earnings ratio of -8.56 and a beta of 0.45.

Institutional Investors Weigh In On OmniAb

Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in shares of OmniAb in the 1st quarter worth approximately $25,000. Jane Street Group LLC grew its holdings in shares of OmniAb by 26.3% in the first quarter. Jane Street Group LLC now owns 80,778 shares of the company’s stock valued at $194,000 after acquiring an additional 16,823 shares in the last quarter. JPMorgan Chase & Co. increased its position in shares of OmniAb by 28.3% during the second quarter. JPMorgan Chase & Co. now owns 793,734 shares of the company’s stock valued at $1,381,000 after acquiring an additional 175,297 shares during the last quarter. Rhumbline Advisers increased its position in shares of OmniAb by 6.0% during the second quarter. Rhumbline Advisers now owns 160,728 shares of the company’s stock valued at $280,000 after acquiring an additional 9,163 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in OmniAb by 17.0% during the second quarter. Invesco Ltd. now owns 109,613 shares of the company’s stock worth $191,000 after acquiring an additional 15,912 shares during the period. 72.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings downgraded OmniAb from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold”.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.